PRQR (PRQR) Stock Price & Analysis
PRQR (PRQR) fell 3.92% to USD 1.47 as of June 10, 2026 at 08:25 UTC, according to Nexqual real-time market data.
PRQR last closed at USD 1.53; the session ranged USD 1.42–1.58 on volume of 476,826 shares. Market capitalization is $154.88M, with a 52-week range of USD 1.33–3.1 (NCM). Source: Nexqual, June 10, 2026 at 08:25 UTC.
Key Statistics (as of June 10, 2026 at 08:25 UTC)
| Price | USD 1.47 |
|---|---|
| Change | ▼ 3.92% (down) |
| Previous Close | USD 1.53 |
| Open | USD 1.55 |
| Day Range | USD 1.42 – 1.58 |
| 52-Week Range | USD 1.33 – 3.1 |
| Volume | 476,826 shares |
| Market Cap | $154.88M |
| Exchange | NCM |
Technical Analysis (PRQR)
Nexqual's technical model rates PRQR "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 08:25 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.58 (neutral) |
| vs SMA50 | Below (USD 1.64) |
| MACD | -0.03 (negative) |
Analyst Ratings (PRQR)
Wall Street analysts rate PRQR "Strong Buy" based on 8 analysts, with a mean price target of USD 8.88 (range USD 4–14), per Nexqual as of June 10, 2026 at 08:25 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 8.88 |
| High Target | USD 14 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (PRQR)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $5.35M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.18 ▲ beat |
| 2025-12-31 | USD -0.09 vs est -0.12 ▲ beat |
| 2025-09-30 | USD -0.12 vs est -0.17 ▲ beat |
| 2025-06-30 | USD -0.14 vs est -0.09 ▼ miss |
Source: Nexqual, June 10, 2026 at 08:25 UTC.
Financials & Fundamentals (PRQR)
| Total Revenue | $13.64M |
|---|---|
| Revenue Growth (YoY) | -57.10% |
| Gross Margin | +100.00% |
| Operating Margin | -671.37% |
| Profit Margin | +0.00% |
| ROE | -78.07% |
| Debt / Equity | 41.85 |
| Current Ratio | 2.48 |
| Total Cash | $81.09M |
| Total Debt | $15.73M |
| Free Cash Flow | $-22.50M |
Source: Nexqual, June 10, 2026 at 08:25 UTC.
Financial Health Score (PRQR)
Nexqual rates PRQR's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 08:25 UTC.
| Growth | Critical — Revenue -11% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $81M cash vs $16M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$22M, burning cash |
| Efficiency | Critical — ROE -78%, ROA -23.1% |
Ownership (PRQR)
| Insider Ownership | +17.66% |
|---|---|
| Institutional Ownership | +48.94% |
| Shares Outstanding | 105.36M |
| Float | 64.35M |
| Short % of Float | +1.24% |
Source: Nexqual, June 10, 2026 at 08:25 UTC.
Leadership (PRQR)
PRQR is led by Daniel Anton de Boer (age 42), Founder, CEO & Executive Director, per Nexqual as of June 10, 2026 at 08:25 UTC.
| Founder, CEO & Executive Director | Daniel Anton de Boer (age 42) |
|---|---|
| Co-Founder, Chief Scientific Officer & Executive Director | Gerard Platenburg (age 61) |
| Chief Financial Officer | Dennis Hom (age 50) |
| Vice President of Investor Relations & Corporate Communications | Sarah Cue Kiely |
Major Backers & Investors (PRQR)
Notable institutional backers of PRQR include Adage Capital Partners GP L.L.C., Privium Fund Management B.V., Aberdeen Group plc, according to Nexqual as of June 10, 2026 at 08:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Adage Capital Partners GP L.L.C. | 5.94% |
| Privium Fund Management B.V. | 5.19% |
| Aberdeen Group plc | 3.15% |
| abrdn World Healthcare Fund | 3.15% |
| Affinity Asset Advisors, Llc | 2.33% |
| Sio Capital Management, LLC | 1.86% |
| DAFNA Capital Management, LLC | 1.49% |
| Kynam Capital Management, LP | 1.49% |
Source: Nexqual, June 10, 2026 at 08:25 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
| AFMDQ | Affimed N.V. | USD 0 | ▲ 0% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.72 | ▲ 5.52% |
| WVE | Wave Life Sciences Ltd. | USD 5.78 | ▲ 0.87% |
| PTGX | Protagonist Therapeutics, Inc. | USD 105.87 | ▲ 8.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:25 UTC. This page is informational and not investment advice.